25 September, 2014 by The TZ Newswire Staff Comments Off on Initial Jobless Claims Rise 12k, Hover Near 14-Year Lows
Initial Jobless Claims Rise 12k, Hover Near 14-Year Lows
After last week’s tumble to 280k, initial jobless claims rose modestly this week to 293k (slightly better than expected) but remain near a dovish-Yellen-crushing 14-year low. Continuing claims also remain at cycle lows around 2.4 million (rising modestly – by 7k – this week). The labor department cites no unusual or estimated claims this week. It appears this is as good as it gets and the Fed has reached its ‘job-creating’ mirage peak…
As good as it gets…
25 September, 2014 by The TZ Newswire Staff Comments Off on Economic Report: U.S. jobless claims climb by 12,000
Economic Report: U.S. jobless claims climb by 12,000
The number of people who applied for unemployment benefits rose by 12,000 to 293,000 in mid-September, but weekly claims continued to hover near an eight-year bottom amid a very low rate of layoffs.
read more
25 September, 2014 by The TZ Newswire Staff Comments Off on Unusual Activity
Unusual Activity
25 September, 2014 by The TZ Newswire Staff Comments Off on High-Yield Stocks for Dividend Investing: Apollo Investment Corporation
High-Yield Stocks for Dividend Investing: Apollo Investment Corporation
Business development companies offer great dividends for investors, but is Apollo the right pick?
25 September, 2014 by The TZ Newswire Staff Comments Off on CLEARING: DTCC Becomes Trade Repository in Canadian Provinces
CLEARING: DTCC Becomes Trade Repository in Canadian Provinces
Depository Trust Clearing Corporation is now entering the Canadian clearing market and is officially designated as an authorized trade repository for derivatives for the Canadian provinces of Ontario, Quebec and Manitoba.
25 September, 2014 by The TZ Newswire Staff Comments Off on Should Pfizer Inc. Buy Actavis plc?
Should Pfizer Inc. Buy Actavis plc?
Pfizer is in a bit of pickle when it comes to generating growth. Although the company is flush with cash, it doesn’t have much in the way of major new drugs in the pipeline and has a mountain of cash locked up abroad. Here is one way Pfizer could solve these lingering problems.
